Checkpoint inhibitors in older patients with advanced non-small cell lung cancer

被引：4

作者：

Reale, Maria Lucia ^{[1
]}

Romano, Gianpiero Diego ^{[1
]}

Paolelli, Loretta ^{[1
]}

Leo, Silvana ^{[1
]}

机构：

[1] Vito Fazzi Hosp, Med Oncol Unit, Via Giuseppe Moscati, I-73100 Lecce, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 188卷

关键词：

Immunotherapy; NSCLC; Elderly patients; Geriatric assessment; ELDERLY-PATIENTS; OPEN-LABEL; PHASE-III; CHEMOTHERAPY TOXICITY; GERIATRIC ONCOLOGY; ITALIAN COHORT; NIVOLUMAB; DOCETAXEL; PEMBROLIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.critrevonc.2023.104056

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer management improving overall survival and providing durable responses with a favorable toxicity profile. New questions have emerged regarding the efficacy and safety of immunotherapy among older adults, typically underrepresented in clinical trials. Several factors have to be taken into account in order to reduce the realistic risk of over or under-treatment of this growing subgroup of patients. In this perspective, geriatric assessment and screening tools should be implemented in clinical practice; moreover older patients' inclusion into adapted-designed clinical trials should be promoted. In this review, we discuss immunotherapy activity in advanced non-small cell lung cancer (NSCLC) older patients, the role of the comprehensive geriatric assessment, treatment toxicity and its management with a focus on future perspectives in this rapidly evolving scenario.

引用

页数：9

共 66 条

[1] Geriatric oncology: challenges for the new century [J].

Balducci, L .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1741-1754

[2] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis [J].

Baxi, Shrujal ;

Yang, Annie ;

Gennarelli, Renee L. ;

Khan, Niloufer ;

Wang, Ziwei ;

Boyce, Lindsay ;

Korenstein, Deborah .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 360

[3] Management of immunotherapy toxicities in older adults [J].

Bhandari, Shruti ;

Gill, Amitoj S. ;

Perez, Cesar A. ;

Jain, Dharamvir .

SEMINARS IN ONCOLOGY, 2018, 45 (04) :226-231

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5]

Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605

[6] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[7] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[8] Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis [J].

Elias, Rawad ;

Giobbie-Hurder, Anita ;

McCleary, Nadine Jackson ;

Ott, Patrick ;

Hodi, F. Stephen ;

Rahma, Osama .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[9]

Franceschi C, 2000, ANN NY ACAD SCI, V908, P244

[10] A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC [J].

Fujimoto, Daichi ;

Miura, Satoru ;

Yoshimura, Kenichi ;

Wakuda, Kazushige ;

Oya, Yuko ;

Haratani, Koji ;

Itoh, Shoichi ;

Uemura, Takehiro ;

Morinaga, Ryotaro ;

Takahama, Takayuki ;

Nakashima, Kazuhisa ;

Tachihara, Motoko ;

Saito, Go ;

Tanizaki, Junko ;

Otsubo, Kohei ;

Ikeda, Satoshi ;

Matsumoto, Hirotaka ;

Hara, Satoshi ;

Hata, Akito ;

Masuda, Takeshi ;

Yamamoto, Nobuyuki .

JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02)

← 1 2 3 4 5 6 7 →